Prognostic Variables Associated With Improved Outcomes in Patients With Stage III NSCLC Treated With Chemoradiation Followed by Consolidation Pembrolizumab: A Subset Analysis of a Phase II Study From the Hoosier Cancer Research Network LUN 14-179

Bilal Anouti, Sandra Althouse, Greg Durm, Nasser Hanna

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

We conducted a retrospective analysis of patients enrolled in the Hoosier Cancer Research Network LUN 14-179. Univariable Cox regression was performed to determine the variables associated with 3 end points: time to metastatic disease or death (TMDD), progression-free survival (PFS), and overall survival (OS). Stage IIIA and longer duration of pembrolizumab might be associated with prolonged TMDD, PFS, and OS for patients with stage III NSCLC treated with chemoradiation followed by pembrolizumab.

Original languageEnglish (US)
Pages (from-to)288-293
Number of pages6
JournalClinical Lung Cancer
Volume21
Issue number3
DOIs
StatePublished - May 2020

Keywords

  • Adjuvant therapy
  • Consolidation
  • Immunotherapy
  • Non–small-cell lung cancer
  • Prognosis

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Fingerprint Dive into the research topics of 'Prognostic Variables Associated With Improved Outcomes in Patients With Stage III NSCLC Treated With Chemoradiation Followed by Consolidation Pembrolizumab: A Subset Analysis of a Phase II Study From the Hoosier Cancer Research Network LUN 14-179'. Together they form a unique fingerprint.

  • Cite this